Patent ductus arteriosus (PDA) remains a prominent clinical challenge in the management of preterm infants. During fetal life, the ductus arteriosus diverts blood away from the underdeveloped lungs, ...

Active treatment of hemodynamically significant patent ductus arteriosus (PDA) in preterm infants within the first 2 weeks of life was associated with worse outcomes than expectant management.

In light of the variability in early ductal constriction and the early hemodynamic impact of an unconstricted DA, it may be that closure after the first 24 hours of life may be too late. Further, the ...

Merit Medical Systems initiates a study to evaluate the Bloom Micro Occluder System for treating patent ductus arteriosus in premature infants. Merit Medical Systems, Inc. has announced the enrollment ...

Please provide your email address to receive an email when new articles are posted on . Compared with surgical ligation, transcatheter closure of the patent ductus arteriosus in infants and neonates ...

Incidence of death or BPD does not differ with expectant management versus active treatment for preterm infants with protocol-defined PDA.

Intravenous indomethacin is more effective than intravenous acetaminophen in treating hemodynamically significant PDAs (hsPDAs) in very low birth weight (VLBW) infants, according to new Le Bonheur ...

The Society for Cardiovascular Angiography & Interventions (SCAI) has published a new position statement that provides best-practice guidance for the treatment of patent ductus arteriosus (PDA) using ...

Larger DA diameter was significantly related to this low systemic blood flow in the early hours after birth. [13] By the time the PDA became clinically apparent (mean 72 hours), the infants were ...